NCT03283943View on ClinicalTrials.gov

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

PHASE1UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

December 16, 2020

Study Completion Date

December 16, 2020

Conditions
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Interventions
RADIATION

Focal radiotherapy

Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).

DRUG

Durvalumab

Durvalumab 1500 mg IV every 28 days

Trial Locations (1)

V5Z 4E6

RECRUITING

BC Cancer Agency, Vancouver

Sponsors

Collaborators (1)

Ozmosis Research Inc.
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

lead

British Columbia Cancer Agency

OTHER

NCT03283943 - PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | Biotech Hunter | Biotech Hunter